Isotretinoin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Isotretinoin: From Severe Cystic Acne to Malignant Renovascular Hypertension
One-Sentence Summary
Isotretinoin (13-cis-retinoic acid) is a retinoid originally used to treat severe cystic acne by regulating epidermal cell differentiation and sebaceous gland activity. The TxGNN model predicts a possible link to Malignant Renovascular Hypertension, but this prediction is currently supported by no clinical trials and no published literature — it is a model-score-only signal with no pharmacological plausibility identified to date.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe cystic acne (drug-level narrative only; no SAHPRA licence data available) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Note: A second, near-identical prediction — Malignant Hypertensive Renal Disease (score 99.01%, rank 4773) — carries the same L5/Hold status and is subject to the same caveats below.
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data for isotretinoin is currently not available in this evidence pack [DG002]. Based on known pharmacology, isotretinoin acts on retinoic acid receptors to regulate epidermal cell differentiation and sebum production, and its efficacy in severe cystic acne is well established clinically.
There is currently no identified mechanistic pathway connecting isotretinoin to malignant renovascular hypertension or its associated renal pathology (vascular endothelial injury, fibrinoid necrosis). Isotretinoin has no known action on the renin-angiotensin system or vascular smooth muscle. In fact, retinoid-class drugs carry known safety signals — including intracranial hypertension (pseudotumor cerebri) and potential effects on renal function and lipid metabolism — that run counter to, rather than support, a therapeutic role in severe hypertensive vascular/renal disease.
This prediction should therefore be treated as a knowledge-graph-derived signal only, without pharmacological or clinical support at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
No SAHPRA registrations were found for isotretinoin in this evidence pack (market status: Not Marketed, 0 licences). Registration status should be independently verified against the current SAHPRA register before any further evaluation.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: TFDA/SAHPRA label warnings and contraindications for isotretinoin are a data gap flagged as Blocking [DG001] — this must be resolved before any safety assessment can proceed, given isotretinoin’s known teratogenicity and psychiatric/hepatic monitoring requirements.)
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5, model-prediction-only signal with zero supporting clinical trials or literature, no established mechanistic rationale, and a known safety profile that is directionally inconsistent with the proposed indication. No SAHPRA market presence exists to anchor a real-world safety baseline.
To proceed, the following is needed:
- TFDA/SAHPRA-approved Professional Information (warnings, contraindications) [DG001 — Blocking]
- Confirmed mechanism of action data from DrugBank or primary literature [DG002]
- Any preclinical or mechanistic studies linking retinoids to renovascular/hypertensive renal pathology
- Independent pharmacological review before this candidate advances beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.